Błasiak M, Pacyk G, Zawadowicz B
Oddziału Chorób Wewnetrznych Wojewódzkiego Szpitala Zespolonego w Czestochowie.
Pol Tyg Lek. 1996 Mar;51(10-13):150-2.
During a 4-year period, 59 patients with the acute myocardial infarction were treated at the ICU of the district hospital. Streptokinase, used for the treatment, was given i.v. after and average period of 3 hours following the onset of stenocardia. Elaborated protocol was observed as to the selection of patients for thrombolytic therapy and its tactics. Basing on the indirect criteria of reperfusion, a recanalization of the occluded artery was noted in 74.6% of the treated patients. Complications occurred most frequently during the first 24 hours of the hospitalisation. None was serious enough to require special therapeutic measures. Complications of the thrombolytic treatment were less frequent after the first day of the hospitalisation. Thrombolytic treatment of the acute myocardial infarction with intravenous streptokinase is safe and effective, and may successfully be carried out also in district hospitals in which cardiac catheterization and cardiosurgery are inaccessible.
在4年期间，地区医院重症监护病房治疗了59例急性心肌梗死患者。用于治疗的链激酶在心绞痛发作后平均3小时静脉注射。在选择溶栓治疗患者及其策略方面遵循了详细的方案。根据再灌注的间接标准，74.6%的接受治疗的患者闭塞动脉实现了再通。并发症最常发生在住院的头24小时内。没有严重到需要特殊治疗措施的情况。住院第一天后溶栓治疗的并发症较少。静脉注射链激酶溶栓治疗急性心肌梗死是安全有效的，在无法进行心导管检查和心脏手术的地区医院也可以成功开展。
